Estrogen therapy is not categorically safe or dangerous. Its risk profile shifts dramatically depending on when you start it relative to menopause, how it enters your body, whether a progestogen is added, and what your individual risk factors are. For women under 60 or within ten years of menopause, the evidence consistently shows that the benefits of estrogen therapy for managing menopausal symptoms outweigh the risks for most people, and some data suggest it may even reduce overall mortality. For women who start much later, particularly in their 70s, the balance tips the other direction. That distinction, sometimes called the “timing hypothesis,” is the single most important thing to understand about estrogen safety.
How the Evidence Shifted
Much of the fear around estrogen therapy traces to the Women’s Health Initiative (WHI), a large set of clinical trials launched in the 1990s. When early results were reported in 2002, headlines declared that hormone therapy raised the risk of heart disease, stroke, blood clots, and breast cancer. Millions of women stopped their prescriptions almost overnight, and many doctors stopped prescribing them altogether.
The problem was that the WHI enrolled women with an average age of 63, and many participants were a decade or more past menopause. Later analyses broke the results down by age and told a very different story. For women aged 50 to 59 who took estrogen alone, adverse events actually decreased by about 19 per 10,000 women per year compared to placebo. For women aged 70 to 79, adverse events increased substantially. Even for the combined estrogen-plus-progestin arm, women in their 50s had far fewer excess risks than older participants.
A 2025 reanalysis of the same WHI data reinforced this pattern, finding that hormone therapy relieved moderate and severe hot flashes and night sweats in women aged 50 to 59 without raising the risk of atherosclerotic cardiovascular disease, including heart attack, stroke, and peripheral arterial disease. Among women in their 70s, cardiovascular risk did increase. The authors concluded that the results “underscore the need to avoid” hormone therapy in women after age 70.
Heart Disease and When You Start
The timing hypothesis has held up across multiple study designs. Subanalyses of the WHI by age group, plus more recent randomized trials like the Kronos Early Estrogen Prevention Study and the Early Versus Late Intervention Trial, demonstrate that the risk of adverse cardiovascular events is low for women under 60 or within ten years of menopause.
Two meta-analyses found that hormone therapy initiated in women under 60 or less than ten years past menopause reduced all-cause mortality by about 39% and coronary heart disease by about 32% compared to placebo. When therapy was initiated in women over 60 or more than ten years past menopause, those benefits disappeared entirely.
This does not mean estrogen is a heart-disease treatment. No major medical society recommends starting hormone therapy solely for cardiovascular protection. But for women who are already candidates for symptom relief, the cardiovascular data are reassuring rather than alarming when therapy starts early.
Blood Clots and How the Delivery Route Matters
Blood clots, specifically venous thromboembolism, are one of estrogen therapy’s most well-established risks. But the size of that risk depends heavily on whether estrogen is swallowed as a pill or absorbed through the skin as a patch, gel, or spray.
When estrogen is taken orally, it passes through the liver before reaching the rest of the body. That “first-pass” effect stimulates the production of clotting factors. Transdermal estrogen bypasses the liver, and the difference in clot risk is striking. A systematic review and meta-analysis comparing the two routes found that oral estrogen carried roughly 60% higher risk of a first venous clot than transdermal estrogen. A separate large cohort study found that the rate of venous thromboembolism was significantly lower for transdermal patch users than for oral estrogen users even after adjusting for other risk factors. Another meta-analysis confirmed that oral estrogen increased clot risk while transdermal preparations did not.
For women who have elevated baseline clot risk due to obesity, a history of blood clots, or certain genetic mutations, transdermal estrogen is strongly preferred. The evidence is consistent enough that many clinicians now default to patches or gels for most patients, reserving oral estrogen for situations where transdermal options are impractical.
Stroke Risk
Stroke is another area where dose and delivery route make a meaningful difference. Standard-dose oral hormone therapy increases stroke risk by roughly a third, and the elevated risk appears limited mainly to ischemic strokes, the kind caused by a blocked blood vessel. A large Danish cohort study found that the first year of hormone therapy use was associated with about double the hazard for any stroke, with the elevated risk persisting at a lower level during continued use and even after stopping.
Low-dose transdermal estrogen tells a different story. In a nested case-control study using the UK’s General Practice Research Database, low-dose patches were not associated with increased stroke risk, while high-dose patches and all oral formulations were. A separate analysis found that transdermal estrogen at doses of 50 micrograms per day or less showed no significant stroke association.
The pattern here mirrors the blood clot data: transdermal estrogen at low doses appears to sidestep much of the stroke risk that gave oral estrogen its reputation. This is one reason current guidelines favor the lowest effective dose delivered through the skin whenever possible.
Breast Cancer
Breast cancer risk is where the distinction between estrogen alone and estrogen combined with a progestogen becomes critical. In the WHI, estrogen-only therapy was actually associated with fewer breast cancer cases and lower breast cancer mortality compared to placebo. The combined estrogen-plus-progestin arm, by contrast, showed a meaningful increase in breast cancer cases.
This finding has been confirmed by broader reviews. Estrogen-plus-progestin therapy has consistently been linked to higher breast cancer risk in postmenopausal women, while estrogen alone has little impact on breast cancer risk in women who had natural or surgical menopause. The type of progestogen matters too: synthetic progestins like medroxyprogesterone acetate appear to carry more risk than micronized progesterone, though head-to-head trial data comparing the two are limited.
A practical consequence: women who have had a hysterectomy can take estrogen alone and avoid the added breast cancer risk that comes with a progestogen. Women who still have a uterus need a progestogen to protect against endometrial cancer, which brings us to the next tradeoff.
Endometrial and Ovarian Cancer
Estrogen stimulates the lining of the uterus. Taken without a progestogen in women who still have a uterus, it promotes endometrial thickening that can progress to cancer. This is why unopposed estrogen is prescribed only after hysterectomy. For women with an intact uterus, adding a progestogen effectively eliminates this excess endometrial risk.
Ovarian cancer is a smaller and less certain concern. A large meta-analysis pooling data from 52 epidemiological studies estimated that women who use hormone therapy for five years starting around age 50 face roughly one extra ovarian cancer case per 1,000 users and about one extra ovarian cancer death per 1,700 users. That is a real but small absolute risk, and it applies to both estrogen-only and combined therapy. Most clinicians consider this risk worth discussing but not a reason to withhold treatment when symptoms are significant.
Bone Protection and What Happens After Stopping
Estrogen is one of the most effective tools for preventing osteoporotic fractures in postmenopausal women. All hormone therapy preparations, including low-dose and non-oral routes, have been shown to protect bone density. Estrogen reduces fracture risk across all major skeletal sites, even in women who are not yet at high fracture risk.
The catch is that bone protection lasts only while you are on therapy. After stopping, bone loss accelerates rapidly. One study found that the annual rate of vertebral bone loss within the first two years after stopping hormone therapy was essentially identical to the rate seen in the first two years after menopause in untreated women, roughly 1.5% per year. A large nested case-control study found that current hormone therapy use was associated with about 25% lower fracture risk, but after discontinuation the protection faded and fracture risk temporarily rose slightly above the level of women who had never used hormones at all, before eventually settling back down.
This rebound means that stopping hormone therapy is not a neutral event for bones. Women who discontinue after years of use may need to transition to another bone-protective medication, particularly if they have other risk factors for osteoporosis.
Brain Health and Dementia
The relationship between estrogen and the brain is one of the most contested areas in this field. Observational studies have repeatedly suggested that women who start hormone therapy near menopause have lower rates of Alzheimer’s disease and dementia, consistent with a “window” hypothesis similar to the one for cardiovascular disease. One comprehensive review concluded that estrogen’s protective effect on dementia appears strongest when therapy begins within the first five years of menopause.
But the randomized trial data are more complicated. When the WHI tested hormone therapy in women aged 65 and older, it actually increased dementia risk. And a recent study using brain imaging found that in women over 70, hormone therapy users accumulated tau protein, a hallmark of Alzheimer’s pathology, faster than non-users in brain regions vulnerable to the disease. In women under 70, that association was negligible. A large Danish registry study found that even estrogen-only therapy used before age 55 was associated with a higher hazard of dementia.
The honest summary is that estrogen probably does something meaningful in the brain, but whether that something is protective or harmful depends on when it starts and how long it continues. The evidence is not yet consistent enough to recommend or avoid hormone therapy specifically for cognitive reasons. Clinicians generally treat brain health as a secondary consideration rather than a primary reason to prescribe or withhold estrogen.
Vaginal Estrogen Is a Different Conversation
Low-dose vaginal estrogen, delivered as a cream, ring, or tablet inserted locally, acts almost entirely on the tissues of the vagina, vulva, and urinary tract. Very little reaches the bloodstream. This makes it a fundamentally different risk proposition from systemic hormone therapy.
A systematic review found vaginal estrogen products to be clinically effective for treating the dryness, irritation, painful sex, and urinary symptoms that commonly develop after menopause, with few adverse effects even at very low doses. Because systemic absorption is minimal, vaginal estrogen does not appear to carry the cardiovascular or clotting risks associated with oral therapy.
Even in women with a history of breast cancer, where systemic estrogen is typically avoided, a large claims-based analysis found no increased risk of cancer recurrence within five years among those using vaginal estrogen. Many oncologists now consider low-dose vaginal estrogen acceptable for breast cancer survivors with severe urogenital symptoms, though practice varies and the conversation should involve the treating oncologist.
Metabolic Effects
Menopause is associated with increasing insulin resistance, and estrogen therapy appears to partially counteract this. A systematic review and meta-analysis found that hormone therapy significantly reduced a standard measure of insulin resistance in non-diabetic postmenopausal women, with estrogen alone showing a larger effect than the combination of estrogen and progestogen. This does not mean estrogen prevents diabetes in a clinically meaningful way, but it does suggest that the metabolic profile during hormone therapy use is somewhat more favorable than without it.
Genetic Risk Factors That Change the Equation
Not everyone metabolizes estrogen the same way, and certain inherited traits can dramatically shift the risk calculation. The most well-studied example is Factor V Leiden, a clotting mutation carried by roughly 5% of people of European descent. Women who carry this mutation and take estrogen face a sharply elevated risk of venous thromboembolism. One study in a British-South Asian cohort found that women with the Factor V Leiden mutation who were prescribed estrogen had more than double the rate of blood clots compared to women without the mutation.
Other inherited clotting disorders, like prothrombin gene mutations, carry similar implications. Some clinicians now recommend testing for common thrombophilias before prescribing hormone therapy, particularly in women with a personal or family history of blood clots. If a clotting mutation is found, transdermal estrogen at the lowest effective dose becomes especially important, since transdermal delivery avoids the liver-mediated increase in clotting factors that makes oral estrogen so much riskier for this group.
Estrogen in Gender-Affirming Care
Transgender women and transfeminine individuals who take estrogen as part of gender-affirming hormone therapy face overlapping but distinct safety questions. The doses used are often higher than typical menopausal hormone therapy, and treatment typically continues for decades rather than years.
A literature review found that transgender women on estrogen-based hormone therapy appear to have a higher risk of heart attack than cisgender women, though not higher than cisgender men. Stroke risk was elevated compared to both groups. The review also found increased risk of venous thromboembolism, particularly when older formulations like ethinyl estradiol were used. One of the largest studies to date reported a venous clot rate of about 1% over an average follow-up of roughly five years in transgender women, with much of that risk tied to ethinyl estradiol, which has since been largely abandoned in favor of estradiol valerate or transdermal estradiol.
Bone density in transgender women tends to improve in the lumbar spine with estrogen therapy, though data on fracture risk remain limited. Current clinical practice guidelines recommend the same general safety monitoring used for cisgender women on hormone therapy, including attention to clot risk, cardiovascular health, and dose optimization, with the added awareness that long-term safety data spanning decades of use are still accumulating.
Why Compounded Hormones Are Not Interchangeable With FDA-Approved Products
Custom-compounded hormone preparations, often marketed as “bioidentical,” have become extremely popular. In the United States, compounding pharmacies mix estrogen (and sometimes progesterone) into creams, troches, pellets, or capsules tailored to an individual prescription. While the hormones themselves may be molecularly identical to those in FDA-approved products, the difference lies in oversight. FDA-approved hormone therapies must meet strict manufacturing standards for purity, potency, and consistency. Compounded preparations do not undergo the same regulatory scrutiny. A review of the compounding industry noted that manufacturing quality is not ensured, and some compounding pharmacies have been found making misleading claims about safety advantages that lack evidence.
The practical concern is not that bioidentical estradiol is inherently different from what is in an FDA-approved patch. It is that a compounded product may deliver an inconsistent dose, contain contaminants, or lack the quality controls that make clinical trial data relevant to what you are actually putting in your body. Major medical societies, including the North American Menopause Society, recommend FDA-approved formulations as the standard of care and caution against assuming compounded products are safer simply because they are marketed as natural.
Contraceptive Estrogen Versus Menopausal Estrogen
Birth control pills and menopausal hormone therapy both contain estrogen, but they use different molecules at very different doses. Most combined oral contraceptives use ethinyl estradiol, a synthetic estrogen designed to be potent enough to suppress ovulation. Ethinyl estradiol has a far greater impact on liver protein production than the estradiol used in menopausal therapy, which translates into a more pronounced effect on clotting factors and a higher thrombotic risk per unit of activity. Newer contraceptives using estradiol valerate or estetrol aim to narrow that gap, offering a metabolic and vascular profile closer to natural estradiol.
This distinction matters because risk data from oral contraceptive studies cannot be directly applied to menopausal hormone therapy, and vice versa. The clot risk from a standard birth control pill in a 25-year-old and the clot risk from a low-dose estradiol patch in a 52-year-old are driven by different molecules, different doses, and different baseline physiology. Treating them as equivalent leads to confused decision-making on both ends.
Overall Mortality
Perhaps the most reassuring piece of the safety picture is what happens when researchers look at death from any cause. A nationwide Danish cohort study following women over a long period found that past or present use of menopausal hormone therapy was associated with a modest reduction in all-cause mortality, with an adjusted hazard ratio of 0.96. The benefit appeared to grow with longer use, reaching its lowest point around three to ten years of therapy, before narrowing with very long use beyond ten years.
Earlier meta-analyses focusing specifically on women who started therapy before age 60 found larger effects, with all-cause mortality reduced by nearly 40% compared to placebo across 30 randomized trials. That number likely overstates the benefit in routine clinical practice, since trial populations differ from the general population, but the direction of the signal is consistent: starting hormone therapy early does not appear to shorten your life, and it may modestly extend it.
The North American Menopause Society’s 2022 position statement reflects this evolving evidence, recommending that treatment be individualized to maximize benefits and minimize risks, with periodic reassessment over time. The days of blanket warnings against hormone therapy are over, but so is the era of prescribing it to everyone. The question is no longer whether estrogen is safe in some abstract sense but whether it is safe for you, given your age, symptoms, medical history, and how it is delivered.